Panobinostat for the Treatment of Multiple Myeloma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20151101

A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors.

Archives of toxicology 20150101

Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.

Molecular cancer therapeutics 20140501

SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells.

Cell death & disease 20130501

Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways.

Cancer letters 20121230

Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.

Molecular pharmacology 20121201

Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.

Journal of medicinal chemistry 20121126

Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors.

Investigational new drugs 20121001

Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients.

Cancer chemotherapy and pharmacology 20121001

[Inhibitory effect of histone deacetylase inhibitor LBH589 on multiple myeloma MM1R cells in vitro].

Zhongguo shi yan xue ye xue za zhi 20121001

Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines.

Experimental cell research 20120910

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.

Leukemia & lymphoma 20120901

Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.

Leukemia & lymphoma 20120901

A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors.

Cancer chemotherapy and pharmacology 20120901

LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120801

Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.

Cancer chemotherapy and pharmacology 20120801

Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation.

Experimental hematology 20120701

Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.

Gastroenterology 20120701

Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.

The Journal of clinical endocrinology and metabolism 20120701

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120620

Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma--can they make one of medical oncology's chemotherapy success stories more successful?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120620

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors.

Investigational new drugs 20120601

Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy.

Leukemia 20120601

Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro.

Leukemia 20120601

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

Journal of hepatology 20120601

Bortezomib and panobinostat combination is effective against PTCL.

Leukemia research 20120601

Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589).

Drug metabolism and disposition: the biological fate of chemicals 20120501

Panobinostat for the treatment of multiple myeloma.

Expert opinion on investigational drugs 20120501

The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.

Blood 20120426

The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120415

LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.

Leukemia research 20120401

Fludarabine and a histone deacetylase inhibitor - strange bedfellows.

Leukemia research 20120401

Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.

Molecular cancer therapeutics 20120401

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.

Journal of neuro-oncology 20120301

Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.

Anticancer research 20120301

KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.

Blood 20120209

Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia.

Blood 20120202

Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.

International journal of cancer 20120201

The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer.

Cancer chemotherapy and pharmacology 20120201

Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120115

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.

British journal of cancer 20120103

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome.

American journal of hematology 20120101

HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20120101

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.

Breast cancer research : BCR 20120101

ING1 and 5-azacytidine act synergistically to block breast cancer cell growth.

PloS one 20120101

Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines.

BMC cancer 20120101

The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.

Investigational new drugs 20111201

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.

Blood 20111117

Development and validation of ultra high performance liquid chromatography-mass spectrometry method for LBH589 in mouse plasma and tissues.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20111115

Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy.

Breast cancer research and treatment 20111101

Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia.

Current cancer drug targets 20111101

Discovery, synthesis, and biological evaluation of novel SMN protein modulators.

Journal of medicinal chemistry 20110922

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.

Cancer chemotherapy and pharmacology 20110901

[Effect of RAD001 or plus LBH589 on the proliferation, apoptosis and drug resistance in chemoresistant acute myeloid leukemic cells].

Zhonghua yi xue za zhi 20110830

A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma.

Cancer investigation 20110801

[Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110801

Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.

Journal of medicinal chemistry 20110714

Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat.

International journal of cancer 20110601

Clinical development of panobinostat in classical Hodgkin's lymphoma.

Expert review of hematology 20110601

Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells.

Taiwanese journal of obstetrics & gynecology 20110601

The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.

Cancer research 20110515

Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.

Haematologica 20110501

Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.

Journal of medicinal chemistry 20110428

LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway.

Leukemia 20110401

The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients.

Leukemia research 20110301

A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors.

Clinical advances in hematology & oncology : H&O 20110301

Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.

Free radical biology & medicine 20110115

Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.

PloS one 20110101

Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.

PloS one 20110101

Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation.

BMC cancer 20110101

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists.

Blood 20101209

To selectivity and beyond.

Nature biotechnology 20101201

Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.

International journal of cancer 20101101

Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.

Clinical cancer research : an official journal of the American Association for Cancer Research 20101001

Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.

Molecular cancer therapeutics 20100801

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.

Haematologica 20100501

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.

Cancer chemotherapy and pharmacology 20100501

Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells.

Molecular cancer therapeutics 20100401

IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.

Blood 20100325

The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition.

Cellular and molecular life sciences : CMLS 20100301

Chemical phylogenetics of histone deacetylases.

Nature chemical biology 20100301

Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.

The Prostate 20100201

Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.

Journal of medicinal chemistry 20100128

Induction of TAp63 by histone deacetylase inhibitors.

Biochemical and biophysical research communications 20100122

The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis.

Cellular oncology : the official journal of the International Society for Cellular Oncology 20100101

The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.

Onkologie 20100101

c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589.

PloS one 20100101

Polycomb target genes are silenced in multiple myeloma.

PloS one 20100101

Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells.

PloS one 20100101

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

Blood 20091203

The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.

Leukemia 20091201

LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate.

Human molecular genetics 20091001

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.

Blood 20091001

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

British journal of haematology 20091001

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.

Blood 20090924

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.

Cancer letters 20090808

The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer.

Molecular cancer therapeutics 20090801

Clinical studies of histone deacetylase inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090615

High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090615

Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.

Anti-cancer drugs 20090601

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.

Future oncology (London, England) 20090601

Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells.

Cancer biology & therapy 20090501

Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.

Blood 20090423

Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.

Journal of medicinal chemistry 20090423

A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma.

International journal of radiation oncology, biology, physics 20090301

Caspase cleavage of Itch in chronic lymphocytic leukemia cells.

Biochemical and biophysical research communications 20090213

A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090201

Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090201

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.

BMC medical genomics 20090101

The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.

Critical reviews in oncology/hematology 20081001

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.

Blood 20081001

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20080715

Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.

World journal of gastroenterology 20080621

Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion.

Cancer research 20080615

Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.

Neuro-oncology 20080601

Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research 20080601

Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.

Clinical cancer research : an official journal of the American Association for Cancer Research 20080515

Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells.

Molecular cancer research : MCR 20080501

Histone deacetylase inhibitors in lymphoma and solid malignancies.

Expert review of anticancer therapy 20080301

Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB.

Leukemia research 20080201

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.

The Biochemical journal 20080115

Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.

World journal of gastroenterology 20070921

Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.

Molecular cancer therapeutics 20070901

Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.

Haematologica 20070401

Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.

Clinical cancer research : an official journal of the American Association for Cancer Research 20070215

Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation.

Cancer biology & therapy 20070101

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

Blood 20061115

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.

Blood 20060715

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

Cancer research 20060601

Meeting highlights from: 47th Annual Meeting of the American Society of Hematology December 2005, Atlanta, GA.

Clinical lymphoma & myeloma 20060501

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

Clinical cancer research : an official journal of the American Association for Cancer Research 20060115

[Novel inhibitors of Bcr-Abl].

Postepy higieny i medycyny doswiadczalnej (Online) 20060101

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

Blood 20050215

The American Society of Hematology--46th Annual Meeting and Exposition. HDAC, Flt and farnesyl transferase inhibitors.

IDrugs : the investigational drugs journal 20050101